References

References

inGENEious Science


  1. Genetics vs. Genomics Fact Sheet. NIH. Accessed August 25, 2020. https://www.genome.gov/about-genomics/fact-sheets/Genetics-vs-Genomics#
  2. Introduction to Genomics. NIH. Accessed August 25, 2020. https://www.genome.gov/About-Genomics/Introduction-to-Genomics 
  3. Human Genome Project FAQ. NIH. Accessed August 25, 2020. https://www.genome.gov/human-genome-project/Completion-FAQ
  4. Genetic Disorders. NIH. Accessed August 25, 2020. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders#
  5. What are the different ways in which a genetic condition can be inherited? Genetics Home Reference. NIH. Accessed September 14, 2020. https://ghr.nlm.nih.gov/primer/inheritance/inheritancepatterns
  6. Morigaki R, Goto S. Brain Sci. 2017;7(6):63.
  7. Huntington disease. Genetics Home Reference. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/condition/huntington-disease 
  8. Lewis RG, Simpson B. Genetics, Autosomal Dominant. StatPearls [Internet]. StatPearls Publishing; 2020 Jan. Accessed August 25, 2020. https://www.ncbi.nlm.nih.gov/books/NBK557512/#:~:text=follow%20this%20law.-,Mechanism,A)%20for%20a%20disorder%20gene
  9. Huntington’s Disease. NORD. Accessed August 2, 2020. https://rarediseases.org/rare-diseases/huntingtons-disease/
  10. Saudou F. Neuron. 2016;89(5):910-926. 
  11. McColgan P, Tabrizi SJ. Eur J Neurol. 2018;25(1):24-34. doi:10.1111/ene.13413
  12. Tabrizi SJ et al.   Lancet Neurol. 2009;8(9):791-801. doi: 10.1016/S1474-4422(09)70170-X
  13. Nopoulos PC et al. Neurobiol Dis. 2010;40(3):544-554.
  14. Rodrigues FB et al. Mov Disord Clin Pract. 2017;4(5):737-742. doi:10.1002/mdc3.12502 
  15. Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord. 2014;29(11):1335-41. doi:10.1002/mds.26011.
  16. Wild EJ, Tabrizi SJ. Chapter 5. Premanifest and early Huntington’s disease. 2013.
  17. McCusker EA. Huntington disease: from premanifest to diagnosis and early care. ACNR. 2019;18(2):12-13.
  18. Soong B-W, Morrison PJ. Handb Clin Neurol. 2018;155:143-174. doi:10.1016/B978-0-444-64189-2.00010-X
  19. Ruano L et al. Neuroepidemiology. 2014;42:174-183. doi:10.1159/000358801
  20. Spinocerebellar ataxia type 3. Orphanet. Accessed August 25, 2020. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
  21. SCA3. Genetics Home References. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/condition/spinocerebellar-ataxia-type-3
  22. Paulson H, Shakkottai V. Spinocerebellar Ataxia Type 3. In: Adam MP et al, eds. GeneReviews® [Internet]. University of Washington, Seattle; 1998 [Updated 2020 Jun 4]. https://www.ncbi.nlm.nih.gov/books/NBK1196/
  23. Kieling C et al. Clin Genet. 2007;72:543-545.
  24. Fabry disease. Genetics Home Reference. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/condition/fabry-disease#genes
  25. How common is Fabry disease? National Fabry Disease Foundation. Accessed August 25, 2020. https://www.fabrydisease.org/index.php/faq/115-how-common-is-fabry-disease#
  26. Schiffman R. Pharmacol & Ther. 2009;122:65-67.
  27. Waldek S et al. Genet Med. 2009;11(11):790-796. doi:https://doi.org/10.1097/GIM.0b013e3181bb05bb
  28. Hemophilia. Genetics Home Reference. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/condition/hemophilia
  29. Iorio A et al. Ann Intern Med. 2019;1-8: doi:10.7326/M19-1208
  30. Hemophilia A. NORD. Accessed August 25, 2020. https://rarediseases.org/rare-diseases/hemophilia-a/
  31. Hemophilia B. NORD. Accessed August 25, 2020. https://rarediseases.org/rare-diseases/hemophilia-b/
  32. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. August 2020. doi:10.1111/hae.14046
  33. Nagel K et al. Haemophilia. 2011;17:872–874.
  34. Witmer C et al. Br J Haematol. 2011;152:211-216
  35. Zanon E, Pasca S. Blood Transfus. 2019; 17:378-84
  36. Darby SC et al. Blood. 2007;110(3):815-825. https://doi.org/10.1182/blood-2006-10-050435
  37. Tagliaferri A et al. Haemophilia. 2010;16(3):437-446. doi:10.1111/j.1365-2516.2009.02188.x
  38. What is gene therapy? Genetics Home Reference. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/primer/therapy/genetherapy
  39. Nobrega C et al. A Handbook of Gene and Cell Therapy. Springer International Publishing; 2020.
  40. Miniarikova J et al. Mol Ther Nucleic Acids. 2016;5(3):e297. doi:10.1038/mtna.2016.7
  41. CRISPR 101: Your Guide to Understanding CRISPR. SYNTHEGO. 2019. Accessed August 25, 2020.
  42. Zhang C et al. Chimeric antigen receptor (CAR) T-cell therapy. StatPearls [Internet]. StatPearls Publishing; 2020 Jan. Accessed August 25, 2020. https://www.ncbi.nlm.nih.gov/books/NBK537294/
  43. FDA. What is gene therapy. Accessed September 11, 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
  44. Lodish H et al. Viruses: structure, function, and uses. In: Molecular Cell Biology. 4th ed. W. H. Freeman; 2000:sect 6.3. Accessed August 25, 2020. https://www.ncbi.nlm.nih.gov/books/ NBK21523/
  45. Samulski JR, Muzyczka N. Annu Rev Virol. 2014;1(1):427-551. doi:10.1146/annurev-virology-031413-085355
  46. Mingozzi F, High KA. Blood. 2013;122(1):23-36. doi:10.1182/blood-2013-01-306647
  47. Hoggan MD et al. Proc Natl Acad Sci U S A. 1966;55(6):1467-1474. doi:10.1073/pnas.55.6.1467
  48. Berns KI, Muzyczka N. Hum Gene Ther. 2017;28(4):308-313. doi:10.1089/hum.2017.048
  49. FDA. Approved Cellular and Gene Therapy Products. Accessed August 26, 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
  50. Boutin S et al. Hum Gene Ther. 2010;21(6):704-712. doi:10.1089/hum.2009.182
  51. Nathwani AC et al. Blood. 2018;132(suppl 1):491.
  52. Pipe S et al. Mol Ther: Methods Clin Dev. 2019;15:170-178. doi:https://doi.org/10.1016/j.omtm.2019.08.015
  53. Niemeyer GP et al. Blood. 2009;113(4):797-806. doi:https://doi. org/10.1182/blood-2008-10-181479
  54. Chira S et al. Oncotarget. 2015;6(31):30675-30703.
  55. Manno CS et al. Nat Med. 2006;12(3):342-347.
  56. Sakuma T et al. Biochem J. 2012:443:603-618.
  57. Strimvelis. European Medicines Agency. Accessed September 23, 200. https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis
  58. Wang D, Gao G. Discov Med. 2014;18(97):67-77.
  59. Ramamoorth M, Narvekar A. J Clin Diagn Res. 2015;9(1):GE01-GE06. doi:10.7860/JCDR/2015/10443.5394
  60. Halder S, Bhattacharyya D. Progress Biophysics Mol Biology. 2013;113:264-283.
Back to top

inGENEious Technology


  1. Samulski JR, Muzyczka N. Annu Rev Virol. 2014;1(1):427-551. doi:10.1146/annurev-virology-031413-085355
  2. Niemeyer GP et al. Blood. 2009;113(4):797-806. doi:https://doi.org/10.1182/blood-2008-10-181479 
  3. Chira S et al. Oncotarget. 2015;6(31):30675-30703. 
  4. Manno CS et al. Nat Med. 2006;12(3):342-347. 
  5. Nobrega C et al. A Handbook of Gene and Cell Therapy. Springer International Publishing; 2020.
  6. McCall L-I et al. PLOS Pathog. 2016;12(5):e1005519 
  7. Lykken EA et al. J Neurodevelop Disord. 2018;10(16). doi:https://doi.org/10.1186/s11689-018-9234-0
  8. Srivastava A. Curr Opin Virol. 2016;21:75-80. doi:10.1016/j.coviro.2016.08.003
  9. Pipe S et al. Mol Ther: Methods Clin Dev. 2019;15:170-178. doi:https://doi.org/10.1016/j.omtm.2019.08.015
  10. Miesbach W et al. Blood. 2018;131(9):1022-1031. doi:10.1182/blood-2017-09-804419
  11. D’Avola D et al. J Hepatol. 2016;65(4):776-783. doi:10.1016/j.jhep.2016.05.012
  12. Tardieu M et al. Lancet Neurol. 2017;16(9):712-720. doi:10.1016/S1474-4422(17)30169-2
  13. Mingozzi F, High KA. Blood. 2013;122(1):23-26. 
  14. Manno CS et al. Nat Med. 2006;12(3):342–347. doi:10.1038/nm1358 
  15. Jiang H et al. Blood. 2006;108(10):3321–3328. doi:10.1182/blood-2006-04-017913 
  16. Boutin S et al. Hum Gene Ther. 2010;21(6):704-712. doi:10.1089/hum.2009.182 
  17. Gorovits B et al. AAPS J. 2016;18(2):311-320. doi:10.1208/s12248-016-9878-1
  18. Nathwani AC et al. Blood. 2006;107(7):2653-2661. doi:10.1182/blood-2005-10-4035
  19. Majowicz A et al. Mol Ther Methods Clin Dev. 2019;14:27-36. doi:10.1016/j.omtm.2019.05.009
  20. Gene therapy study in severe hemophilia A patients with antibodies against AAV5 (270-203). ClinicalTrials.gov identifier: NCT03520712. Updated April 24, 2020. Accessed May 22, 2020. https://clinicaltrials.gov/ct2/show/NCT03520712
  21. Dose confirmation trial of AAV5-hFIXco-Padua. ClinicalTrials.gov identifier: NCT03489291. Updated May 26, 2020. Accessed June 03, 2020. https://clinicaltrials.gov/ct2/show/NCT03489291 
  22. HOPE-B: trial of AMT-061 in severe or moderately severe hemophilia B patients. ClinicalTrials.gov identifier: NCT03569891. Updated May 22, 2020. Accessed June 03, 2020. Accessed May 21, 2020. https://www.clinicaltrials.gov/ct2/show/NCT03569891
  23. Naso MF et al. BioDrugs. 2017;31:317-334.
  24. Felberbaum RS. Biotechnol. 2015;10:702-714.doi:org/10.1002/biot.201400438
  25. Blaha B et al. Characterizing next-generation baculovirus transduction processes. A quality by design-based approach for AAV manufacturing. Presented at ASGCT May 12, 2020. Accessed May 21, 2020.
  26. FDA. Approved Cellular and Gene Therapy Products. Accessed August 26, 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
Back to top

inGENEious Medicine


  1. Samulski JR, Muzyczka N. Annu Rev Virol. 2014;1(1):427-551. doi:10.1146/annurev-virology-031413-085355
  2. Flotte TR. Mol Ther. 2013;21(11):1976-1981. doi:10.1038/mt.2013.226
  3. FDA. FDA Continues Strong Support of Innovation in Development of Gene Therapy Products. Accessed August 28, 2020.
 https://www.fda.gov/news-events/press-announcements/fda-continues-strong-support-innovation-development-genetherapy-
products 
  4. FDA. Approved Cellular and Gene Therapy Products. Accessed August 26, 2020. https://www.fda.gov/vaccines-bloodbiologics/
cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products 
  5. Lykken EA et al. J Neurodevelop Disord. 2018;10:16. doi:https://doi.org/10.1186/s11689-018-9234-0
  6. Nobrega C et al. A Handbook of Gene and Cell Therapy. Springer International Publishing; 2020.

  7. Miniarikova J et al. Mol Ther Nucleic Acids. 2016;5:e297. doi:10.1038/mtna.2016.7
  8. Sands MS. Methods Mol Biol. 2011;807:141-157. doi:10.1007/978-1-61779-370-7_6 
  9. Niemeyer GP et al. Blood. 2009;113(4):797-806. doi:https://doi. org/10.1182/blood-2008-10-181479
  10. Chira S et al. Oncotarget. 2015;6(31):30675-30703.

  11. Manno CS et al. Nat Med. 2006;12(3):342-347.

  12. Nathwani AC et al. Blood. 2018;132(Suppl 1):491.

  13. Doshi BS, Arruda VR. Ther Adv Hematol. 2018;9(9):273-293.

  14. Zolgensma® (onasemnogene abeparvovec-xioi). Prescribing information. AveXis, Inc; 2019.

  15. Luxturna (voretigene neparvovec-rzyl). Prescribing information. Spark Therapeutics, Inc; 2017.
Back to top

inGENEious Resources


  1. Lodish H et al. Viruses: structure, function, and uses. In: Molecular Cell Biology. 4th ed. W. H. Freeman; 2000:sect 6.3. Accessed August 25, 2020. https://www.ncbi.nlm.nih.gov/books/NBK21523/
  2. Samulski JR, Muzyczka N. Annu Rev Virol. 2014;1(1):427-551. doi:10.1146/annurev-virology-031413-085355   
  3. Budworth H, McMurray CT. Methods Mol Biol. 2013;1010:3-17. doi:10.1007/978-1-62703-411-1_1
  4. Naso MF et al. BioDrugs. 2017;31(4):317-334. doi:10.1007/s40259-017-0234-5
  5. Introduction to Genomics. NIH. Accessed August 25, 2020. https://www.genome.gov/About-Genomics/Introduction-to-Genomics
  6. Dunbar CE, High KA, Joung JK, et al. Science. 2018;359(6372):eaan4672. doi:10.1126/science.aan4672
  7. What is noncoding DNA? Genetics Home Reference. NIH. Accessed August 25, 2020. https://ghr.nlm.nih.gov/primer/basics/noncodingdna
  8. Masat E et al. Discov Med. 2013;15(85):379-389.
  9. Halder S, Bhattacharyya D. Progress Biophysics Mol Biology. 2013;113:264-283.
  10. Pipe S et al. Mol Ther: Methods Clin Dev. 2019;15. doi:https://doi.org/10.1016/j.omtm.2019.08.015
  11. Chandler CH. Trends Genet. 2013;29(6):358-366. doi:10.1016/j.tig.2013.01.009
Back to top
Share by: